Changes in peripheral cells immunity after operation and effect of spleen polypeptide on them in patients with traumatic brain injury

MAN Ming-hao; LI Li-hong; YANG Yan-yong; LI Min; GUO Shao-chun

doi:10.13798/j.issn.1009-153X.2016.06.014

Abstract：Objective To study the changes in the peripheral cells immunity after the operation in the patients with traumatic brain injury (TBI) and observe the effect of immunomodulator, spleen polypeptide (SP) on them. Methods we performed a single-center, randomized, controlled, single-blind clinical trial from Jun 10, 2014 to July 1, 2015. Sixty eligible patients with TBI undergoing neurosurgery in neurosurgical intensive care unit (NICU) were randomly divided into the control group (n=30) in which the patients received an intravenous infusion of 250 ml 5%glucose solution per day for 7 days and SP treatment group (n=30) in which the patients received an intravenous infusion of 250 ml 5%glucose solution containing 10 ml SP per day for 7 days. The immunological indexes in the peripheral venous blood were determined before the treatment and 7 days after the treatment and the infectious rates were observed in both the groups. Results The infectious rate (20.0%) was significantly lower in SP treatment group than that (46.7%) in the control group (P<0.05). The levels of monocytes, CD14 and interleukin (IL) 12 expressions in the peripheral venous blood were significantly higher SP treatment group than those control group 7 days after the treatment (P<0.05). The levels of norepinephrine (NA) and IL-2 expressions in the peripheral venous blood was significantly lower in SP treatment groups than in those in the in the control group (P<0.05). However, there were insignificant differences in hospital stay in NICU and GOS 28 days after the treatment between both the groups (P>0.05). Conclusions SP treatment can be helpful to improving the impaired immune function in the patients with TBI, in whom its effect on the prognosis is significant.